Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
2022 · The Lancet Oncology · 406 citations
https://doi.org/10.1016/s1470-2045(22)00226-1